Effect of CyberKnife stereotactic body radiation therapy for hepatocellular carcinoma on hepatic toxicity

Ping Liang,1,* Cheng Huang,2,* Shi-Xiong Liang,2,3 Ye-Fei Li,3 Shang-Xiao Huang,2 Zu-Ping Lian,1 Jian-Min Liu,1 Yang Tang,1 Hai-Jie Lu4 1Department of Radiation Oncology, Ruikang Hospital Affiliated to Guangxi University of Chinese Medicine, 2Department of Radiation Oncology, Cancer Hospital, Guangxi Medical University, Nanning, 3Department of Radiation Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, 4Department of Radiation Oncology, Zhongshan Hospital of Xiamen University, Xiamen, Fujian, People’s Republic of China *These authors contributed equally to this work Objective: To evaluate the safety of CyberKnife stereotactic body radiation therapy (SBRT) for hepatocellular carcinoma (HCC) patients and identify the treatment-related risk factors of hepatic toxicity.Materials and methods: One hundred and four HCC patients treated with CyberKnife SBRT were included in this study between August 2009 and December 2012. The average dose of prescribed radiation was 42.81+-4.78 Gy (28–55 Gy) with the average fraction size of 8–16 Gy to the planning target volume. The average fractions were 3.31+-0.81 (2–6 fractions). Response rates were determined, and the Child–Pugh (CP) score and class following CyberKnife SBRT were obtained to evaluate hepatic toxicity.Results: Seventeen patients experienced progression in CP class and 24 patients experienced CTCAE V. 4.0 grade 2–3 hepatic toxicity during the five-month follow-up period, while no patient experienced grade 4 liver toxicity. Multivariate analysis indicated that only V25 was an independent factor in grade 2–3 hepatic toxicity (P=0.029, <0.05). Radiation-induced hepatic toxicity (RIHT), defined as an increase of at least two points within three months following CyberKnife SBRT, occurred in 13 of the 104 patients (13/104, 12.5%), and only the normal liver tissue was found to be associated with RIHT (P=0.008, <0.05).Conclusion: CyberKnife SBRT is a feasible and safe treatment for HCC with regard to hepatic toxicity, while V25 and normal liver volume may be an independent factor of grade 2–3 hepatic toxicity and RIHT, respectively. Keywords: hepatocellular carcinoma, hepatic toxicity, CyberKnife stereotactic body radiation therapy (SBRT) Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Liang P [verfasserIn] Huang C [verfasserIn] Liang S [verfasserIn] Li Y [verfasserIn] Huang S [verfasserIn] Lian Z [verfasserIn] Liu J [verfasserIn] Tang Y [verfasserIn] Lu H [verfasserIn]

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2016

Schlagwörter:	Hepatocellular carcinoma Hepatic toxicity CyberKnife stereotactic body radiation therapy (SBRT)

Übergeordnetes Werk:	In: OncoTargets and Therapy - Dove Medical Press, 2009, (2016), Seite 7169-7175
Übergeordnetes Werk:	year:2016 ; pages:7169-7175

Links:	Link aufrufen Link aufrufen Journal toc

Katalog-ID:	DOAJ064852555

Internformat


LEADER	01000caa a22002652 4500
001	DOAJ064852555
003	DE-627
005	20230309042653.0
007	cr uuu---uuuuu
008	230228s2016 xx \|\|\|\|\|o 00\| \|\|eng c
035			\|a (DE-627)DOAJ064852555
035			\|a (DE-599)DOAJ8eb24fa1ff7945a998ded7ce01b1000e
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
050		0	\|a RC254-282
100	0		\|a Liang P \|e verfasserin \|4 aut
245	1	0	\|a Effect of CyberKnife stereotactic body radiation therapy for hepatocellular carcinoma on hepatic toxicity
264		1	\|c 2016
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a Ping Liang,1,* Cheng Huang,2,* Shi-Xiong Liang,2,3 Ye-Fei Li,3 Shang-Xiao Huang,2 Zu-Ping Lian,1 Jian-Min Liu,1 Yang Tang,1 Hai-Jie Lu4 1Department of Radiation Oncology, Ruikang Hospital Affiliated to Guangxi University of Chinese Medicine, 2Department of Radiation Oncology, Cancer Hospital, Guangxi Medical University, Nanning, 3Department of Radiation Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, 4Department of Radiation Oncology, Zhongshan Hospital of Xiamen University, Xiamen, Fujian, People’s Republic of China *These authors contributed equally to this work Objective: To evaluate the safety of CyberKnife stereotactic body radiation therapy (SBRT) for hepatocellular carcinoma (HCC) patients and identify the treatment-related risk factors of hepatic toxicity.Materials and methods: One hundred and four HCC patients treated with CyberKnife SBRT were included in this study between August 2009 and December 2012. The average dose of prescribed radiation was 42.81+-4.78 Gy (28–55 Gy) with the average fraction size of 8–16 Gy to the planning target volume. The average fractions were 3.31+-0.81 (2–6 fractions). Response rates were determined, and the Child–Pugh (CP) score and class following CyberKnife SBRT were obtained to evaluate hepatic toxicity.Results: Seventeen patients experienced progression in CP class and 24 patients experienced CTCAE V. 4.0 grade 2–3 hepatic toxicity during the five-month follow-up period, while no patient experienced grade 4 liver toxicity. Multivariate analysis indicated that only V25 was an independent factor in grade 2–3 hepatic toxicity (P=0.029, <0.05). Radiation-induced hepatic toxicity (RIHT), defined as an increase of at least two points within three months following CyberKnife SBRT, occurred in 13 of the 104 patients (13/104, 12.5%), and only the normal liver tissue was found to be associated with RIHT (P=0.008, <0.05).Conclusion: CyberKnife SBRT is a feasible and safe treatment for HCC with regard to hepatic toxicity, while V25 and normal liver volume may be an independent factor of grade 2–3 hepatic toxicity and RIHT, respectively. Keywords: hepatocellular carcinoma, hepatic toxicity, CyberKnife stereotactic body radiation therapy (SBRT)
650		4	\|a Hepatocellular carcinoma
650		4	\|a Hepatic toxicity
650		4	\|a CyberKnife stereotactic body radiation therapy (SBRT)
653		0	\|a Neoplasms. Tumors. Oncology. Including cancer and carcinogens
700	0		\|a Huang C \|e verfasserin \|4 aut
700	0		\|a Liang S \|e verfasserin \|4 aut
700	0		\|a Li Y \|e verfasserin \|4 aut
700	0		\|a Huang S \|e verfasserin \|4 aut
700	0		\|a Lian Z \|e verfasserin \|4 aut
700	0		\|a Liu J \|e verfasserin \|4 aut
700	0		\|a Tang Y \|e verfasserin \|4 aut
700	0		\|a Lu H \|e verfasserin \|4 aut
773	0	8	\|i In \|t OncoTargets and Therapy \|d Dove Medical Press, 2009 \|g (2016), Seite 7169-7175 \|w (DE-627)600307654 \|w (DE-600)2495130-4 \|x 11786930 \|7 nnns
773	1	8	\|g year:2016 \|g pages:7169-7175
856	4	0	\|u https://doaj.org/article/8eb24fa1ff7945a998ded7ce01b1000e \|z kostenfrei
856	4	0	\|u https://www.dovepress.com/effect-of-cyberknife-stereotactic-body-radiation-therapy-for-hepatocel-peer-reviewed-article-OTT \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/1178-6930 \|y Journal toc \|z kostenfrei
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_DOAJ
912			\|a GBV_ILN_11
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_95
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_151
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_206
912			\|a GBV_ILN_213
912			\|a GBV_ILN_230
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_602
912			\|a GBV_ILN_2003
912			\|a GBV_ILN_2005
912			\|a GBV_ILN_2009
912			\|a GBV_ILN_2011
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_2055
912			\|a GBV_ILN_2111
912			\|a GBV_ILN_4012
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4367
912			\|a GBV_ILN_4700
951			\|a AR
952			\|j 2016 \|h 7169-7175

Indexfelder

author_variant	l p lp h c hc l s ls l y ly h s hs l z lz l j lj t y ty l h lh
matchkey_str	article:11786930:2016----::fetfyekietroatcoyaitoteayohptcluac
hierarchy_sort_str	2016
callnumber-subject-code	RC
publishDate	2016
allfields	(DE-627)DOAJ064852555 (DE-599)DOAJ8eb24fa1ff7945a998ded7ce01b1000e DE-627 ger DE-627 rakwb eng RC254-282 Liang P verfasserin aut Effect of CyberKnife stereotactic body radiation therapy for hepatocellular carcinoma on hepatic toxicity 2016 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Ping Liang,1,* Cheng Huang,2,* Shi-Xiong Liang,2,3 Ye-Fei Li,3 Shang-Xiao Huang,2 Zu-Ping Lian,1 Jian-Min Liu,1 Yang Tang,1 Hai-Jie Lu4 1Department of Radiation Oncology, Ruikang Hospital Affiliated to Guangxi University of Chinese Medicine, 2Department of Radiation Oncology, Cancer Hospital, Guangxi Medical University, Nanning, 3Department of Radiation Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, 4Department of Radiation Oncology, Zhongshan Hospital of Xiamen University, Xiamen, Fujian, People’s Republic of China *These authors contributed equally to this work Objective: To evaluate the safety of CyberKnife stereotactic body radiation therapy (SBRT) for hepatocellular carcinoma (HCC) patients and identify the treatment-related risk factors of hepatic toxicity.Materials and methods: One hundred and four HCC patients treated with CyberKnife SBRT were included in this study between August 2009 and December 2012. The average dose of prescribed radiation was 42.81+-4.78 Gy (28–55 Gy) with the average fraction size of 8–16 Gy to the planning target volume. The average fractions were 3.31+-0.81 (2–6 fractions). Response rates were determined, and the Child–Pugh (CP) score and class following CyberKnife SBRT were obtained to evaluate hepatic toxicity.Results: Seventeen patients experienced progression in CP class and 24 patients experienced CTCAE V. 4.0 grade 2–3 hepatic toxicity during the five-month follow-up period, while no patient experienced grade 4 liver toxicity. Multivariate analysis indicated that only V25 was an independent factor in grade 2–3 hepatic toxicity (P=0.029, <0.05). Radiation-induced hepatic toxicity (RIHT), defined as an increase of at least two points within three months following CyberKnife SBRT, occurred in 13 of the 104 patients (13/104, 12.5%), and only the normal liver tissue was found to be associated with RIHT (P=0.008, <0.05).Conclusion: CyberKnife SBRT is a feasible and safe treatment for HCC with regard to hepatic toxicity, while V25 and normal liver volume may be an independent factor of grade 2–3 hepatic toxicity and RIHT, respectively. Keywords: hepatocellular carcinoma, hepatic toxicity, CyberKnife stereotactic body radiation therapy (SBRT) Hepatocellular carcinoma Hepatic toxicity CyberKnife stereotactic body radiation therapy (SBRT) Neoplasms. Tumors. Oncology. Including cancer and carcinogens Huang C verfasserin aut Liang S verfasserin aut Li Y verfasserin aut Huang S verfasserin aut Lian Z verfasserin aut Liu J verfasserin aut Tang Y verfasserin aut Lu H verfasserin aut In OncoTargets and Therapy Dove Medical Press, 2009 (2016), Seite 7169-7175 (DE-627)600307654 (DE-600)2495130-4 11786930 nnns year:2016 pages:7169-7175 https://doaj.org/article/8eb24fa1ff7945a998ded7ce01b1000e kostenfrei https://www.dovepress.com/effect-of-cyberknife-stereotactic-body-radiation-therapy-for-hepatocel-peer-reviewed-article-OTT kostenfrei https://doaj.org/toc/1178-6930 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2016 7169-7175
spelling	(DE-627)DOAJ064852555 (DE-599)DOAJ8eb24fa1ff7945a998ded7ce01b1000e DE-627 ger DE-627 rakwb eng RC254-282 Liang P verfasserin aut Effect of CyberKnife stereotactic body radiation therapy for hepatocellular carcinoma on hepatic toxicity 2016 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Ping Liang,1,* Cheng Huang,2,* Shi-Xiong Liang,2,3 Ye-Fei Li,3 Shang-Xiao Huang,2 Zu-Ping Lian,1 Jian-Min Liu,1 Yang Tang,1 Hai-Jie Lu4 1Department of Radiation Oncology, Ruikang Hospital Affiliated to Guangxi University of Chinese Medicine, 2Department of Radiation Oncology, Cancer Hospital, Guangxi Medical University, Nanning, 3Department of Radiation Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, 4Department of Radiation Oncology, Zhongshan Hospital of Xiamen University, Xiamen, Fujian, People’s Republic of China *These authors contributed equally to this work Objective: To evaluate the safety of CyberKnife stereotactic body radiation therapy (SBRT) for hepatocellular carcinoma (HCC) patients and identify the treatment-related risk factors of hepatic toxicity.Materials and methods: One hundred and four HCC patients treated with CyberKnife SBRT were included in this study between August 2009 and December 2012. The average dose of prescribed radiation was 42.81+-4.78 Gy (28–55 Gy) with the average fraction size of 8–16 Gy to the planning target volume. The average fractions were 3.31+-0.81 (2–6 fractions). Response rates were determined, and the Child–Pugh (CP) score and class following CyberKnife SBRT were obtained to evaluate hepatic toxicity.Results: Seventeen patients experienced progression in CP class and 24 patients experienced CTCAE V. 4.0 grade 2–3 hepatic toxicity during the five-month follow-up period, while no patient experienced grade 4 liver toxicity. Multivariate analysis indicated that only V25 was an independent factor in grade 2–3 hepatic toxicity (P=0.029, <0.05). Radiation-induced hepatic toxicity (RIHT), defined as an increase of at least two points within three months following CyberKnife SBRT, occurred in 13 of the 104 patients (13/104, 12.5%), and only the normal liver tissue was found to be associated with RIHT (P=0.008, <0.05).Conclusion: CyberKnife SBRT is a feasible and safe treatment for HCC with regard to hepatic toxicity, while V25 and normal liver volume may be an independent factor of grade 2–3 hepatic toxicity and RIHT, respectively. Keywords: hepatocellular carcinoma, hepatic toxicity, CyberKnife stereotactic body radiation therapy (SBRT) Hepatocellular carcinoma Hepatic toxicity CyberKnife stereotactic body radiation therapy (SBRT) Neoplasms. Tumors. Oncology. Including cancer and carcinogens Huang C verfasserin aut Liang S verfasserin aut Li Y verfasserin aut Huang S verfasserin aut Lian Z verfasserin aut Liu J verfasserin aut Tang Y verfasserin aut Lu H verfasserin aut In OncoTargets and Therapy Dove Medical Press, 2009 (2016), Seite 7169-7175 (DE-627)600307654 (DE-600)2495130-4 11786930 nnns year:2016 pages:7169-7175 https://doaj.org/article/8eb24fa1ff7945a998ded7ce01b1000e kostenfrei https://www.dovepress.com/effect-of-cyberknife-stereotactic-body-radiation-therapy-for-hepatocel-peer-reviewed-article-OTT kostenfrei https://doaj.org/toc/1178-6930 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2016 7169-7175
allfields_unstemmed	(DE-627)DOAJ064852555 (DE-599)DOAJ8eb24fa1ff7945a998ded7ce01b1000e DE-627 ger DE-627 rakwb eng RC254-282 Liang P verfasserin aut Effect of CyberKnife stereotactic body radiation therapy for hepatocellular carcinoma on hepatic toxicity 2016 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Ping Liang,1,* Cheng Huang,2,* Shi-Xiong Liang,2,3 Ye-Fei Li,3 Shang-Xiao Huang,2 Zu-Ping Lian,1 Jian-Min Liu,1 Yang Tang,1 Hai-Jie Lu4 1Department of Radiation Oncology, Ruikang Hospital Affiliated to Guangxi University of Chinese Medicine, 2Department of Radiation Oncology, Cancer Hospital, Guangxi Medical University, Nanning, 3Department of Radiation Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, 4Department of Radiation Oncology, Zhongshan Hospital of Xiamen University, Xiamen, Fujian, People’s Republic of China *These authors contributed equally to this work Objective: To evaluate the safety of CyberKnife stereotactic body radiation therapy (SBRT) for hepatocellular carcinoma (HCC) patients and identify the treatment-related risk factors of hepatic toxicity.Materials and methods: One hundred and four HCC patients treated with CyberKnife SBRT were included in this study between August 2009 and December 2012. The average dose of prescribed radiation was 42.81+-4.78 Gy (28–55 Gy) with the average fraction size of 8–16 Gy to the planning target volume. The average fractions were 3.31+-0.81 (2–6 fractions). Response rates were determined, and the Child–Pugh (CP) score and class following CyberKnife SBRT were obtained to evaluate hepatic toxicity.Results: Seventeen patients experienced progression in CP class and 24 patients experienced CTCAE V. 4.0 grade 2–3 hepatic toxicity during the five-month follow-up period, while no patient experienced grade 4 liver toxicity. Multivariate analysis indicated that only V25 was an independent factor in grade 2–3 hepatic toxicity (P=0.029, <0.05). Radiation-induced hepatic toxicity (RIHT), defined as an increase of at least two points within three months following CyberKnife SBRT, occurred in 13 of the 104 patients (13/104, 12.5%), and only the normal liver tissue was found to be associated with RIHT (P=0.008, <0.05).Conclusion: CyberKnife SBRT is a feasible and safe treatment for HCC with regard to hepatic toxicity, while V25 and normal liver volume may be an independent factor of grade 2–3 hepatic toxicity and RIHT, respectively. Keywords: hepatocellular carcinoma, hepatic toxicity, CyberKnife stereotactic body radiation therapy (SBRT) Hepatocellular carcinoma Hepatic toxicity CyberKnife stereotactic body radiation therapy (SBRT) Neoplasms. Tumors. Oncology. Including cancer and carcinogens Huang C verfasserin aut Liang S verfasserin aut Li Y verfasserin aut Huang S verfasserin aut Lian Z verfasserin aut Liu J verfasserin aut Tang Y verfasserin aut Lu H verfasserin aut In OncoTargets and Therapy Dove Medical Press, 2009 (2016), Seite 7169-7175 (DE-627)600307654 (DE-600)2495130-4 11786930 nnns year:2016 pages:7169-7175 https://doaj.org/article/8eb24fa1ff7945a998ded7ce01b1000e kostenfrei https://www.dovepress.com/effect-of-cyberknife-stereotactic-body-radiation-therapy-for-hepatocel-peer-reviewed-article-OTT kostenfrei https://doaj.org/toc/1178-6930 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2016 7169-7175
allfieldsGer	(DE-627)DOAJ064852555 (DE-599)DOAJ8eb24fa1ff7945a998ded7ce01b1000e DE-627 ger DE-627 rakwb eng RC254-282 Liang P verfasserin aut Effect of CyberKnife stereotactic body radiation therapy for hepatocellular carcinoma on hepatic toxicity 2016 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Ping Liang,1,* Cheng Huang,2,* Shi-Xiong Liang,2,3 Ye-Fei Li,3 Shang-Xiao Huang,2 Zu-Ping Lian,1 Jian-Min Liu,1 Yang Tang,1 Hai-Jie Lu4 1Department of Radiation Oncology, Ruikang Hospital Affiliated to Guangxi University of Chinese Medicine, 2Department of Radiation Oncology, Cancer Hospital, Guangxi Medical University, Nanning, 3Department of Radiation Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, 4Department of Radiation Oncology, Zhongshan Hospital of Xiamen University, Xiamen, Fujian, People’s Republic of China *These authors contributed equally to this work Objective: To evaluate the safety of CyberKnife stereotactic body radiation therapy (SBRT) for hepatocellular carcinoma (HCC) patients and identify the treatment-related risk factors of hepatic toxicity.Materials and methods: One hundred and four HCC patients treated with CyberKnife SBRT were included in this study between August 2009 and December 2012. The average dose of prescribed radiation was 42.81+-4.78 Gy (28–55 Gy) with the average fraction size of 8–16 Gy to the planning target volume. The average fractions were 3.31+-0.81 (2–6 fractions). Response rates were determined, and the Child–Pugh (CP) score and class following CyberKnife SBRT were obtained to evaluate hepatic toxicity.Results: Seventeen patients experienced progression in CP class and 24 patients experienced CTCAE V. 4.0 grade 2–3 hepatic toxicity during the five-month follow-up period, while no patient experienced grade 4 liver toxicity. Multivariate analysis indicated that only V25 was an independent factor in grade 2–3 hepatic toxicity (P=0.029, <0.05). Radiation-induced hepatic toxicity (RIHT), defined as an increase of at least two points within three months following CyberKnife SBRT, occurred in 13 of the 104 patients (13/104, 12.5%), and only the normal liver tissue was found to be associated with RIHT (P=0.008, <0.05).Conclusion: CyberKnife SBRT is a feasible and safe treatment for HCC with regard to hepatic toxicity, while V25 and normal liver volume may be an independent factor of grade 2–3 hepatic toxicity and RIHT, respectively. Keywords: hepatocellular carcinoma, hepatic toxicity, CyberKnife stereotactic body radiation therapy (SBRT) Hepatocellular carcinoma Hepatic toxicity CyberKnife stereotactic body radiation therapy (SBRT) Neoplasms. Tumors. Oncology. Including cancer and carcinogens Huang C verfasserin aut Liang S verfasserin aut Li Y verfasserin aut Huang S verfasserin aut Lian Z verfasserin aut Liu J verfasserin aut Tang Y verfasserin aut Lu H verfasserin aut In OncoTargets and Therapy Dove Medical Press, 2009 (2016), Seite 7169-7175 (DE-627)600307654 (DE-600)2495130-4 11786930 nnns year:2016 pages:7169-7175 https://doaj.org/article/8eb24fa1ff7945a998ded7ce01b1000e kostenfrei https://www.dovepress.com/effect-of-cyberknife-stereotactic-body-radiation-therapy-for-hepatocel-peer-reviewed-article-OTT kostenfrei https://doaj.org/toc/1178-6930 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2016 7169-7175
allfieldsSound	(DE-627)DOAJ064852555 (DE-599)DOAJ8eb24fa1ff7945a998ded7ce01b1000e DE-627 ger DE-627 rakwb eng RC254-282 Liang P verfasserin aut Effect of CyberKnife stereotactic body radiation therapy for hepatocellular carcinoma on hepatic toxicity 2016 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Ping Liang,1,* Cheng Huang,2,* Shi-Xiong Liang,2,3 Ye-Fei Li,3 Shang-Xiao Huang,2 Zu-Ping Lian,1 Jian-Min Liu,1 Yang Tang,1 Hai-Jie Lu4 1Department of Radiation Oncology, Ruikang Hospital Affiliated to Guangxi University of Chinese Medicine, 2Department of Radiation Oncology, Cancer Hospital, Guangxi Medical University, Nanning, 3Department of Radiation Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, 4Department of Radiation Oncology, Zhongshan Hospital of Xiamen University, Xiamen, Fujian, People’s Republic of China *These authors contributed equally to this work Objective: To evaluate the safety of CyberKnife stereotactic body radiation therapy (SBRT) for hepatocellular carcinoma (HCC) patients and identify the treatment-related risk factors of hepatic toxicity.Materials and methods: One hundred and four HCC patients treated with CyberKnife SBRT were included in this study between August 2009 and December 2012. The average dose of prescribed radiation was 42.81+-4.78 Gy (28–55 Gy) with the average fraction size of 8–16 Gy to the planning target volume. The average fractions were 3.31+-0.81 (2–6 fractions). Response rates were determined, and the Child–Pugh (CP) score and class following CyberKnife SBRT were obtained to evaluate hepatic toxicity.Results: Seventeen patients experienced progression in CP class and 24 patients experienced CTCAE V. 4.0 grade 2–3 hepatic toxicity during the five-month follow-up period, while no patient experienced grade 4 liver toxicity. Multivariate analysis indicated that only V25 was an independent factor in grade 2–3 hepatic toxicity (P=0.029, <0.05). Radiation-induced hepatic toxicity (RIHT), defined as an increase of at least two points within three months following CyberKnife SBRT, occurred in 13 of the 104 patients (13/104, 12.5%), and only the normal liver tissue was found to be associated with RIHT (P=0.008, <0.05).Conclusion: CyberKnife SBRT is a feasible and safe treatment for HCC with regard to hepatic toxicity, while V25 and normal liver volume may be an independent factor of grade 2–3 hepatic toxicity and RIHT, respectively. Keywords: hepatocellular carcinoma, hepatic toxicity, CyberKnife stereotactic body radiation therapy (SBRT) Hepatocellular carcinoma Hepatic toxicity CyberKnife stereotactic body radiation therapy (SBRT) Neoplasms. Tumors. Oncology. Including cancer and carcinogens Huang C verfasserin aut Liang S verfasserin aut Li Y verfasserin aut Huang S verfasserin aut Lian Z verfasserin aut Liu J verfasserin aut Tang Y verfasserin aut Lu H verfasserin aut In OncoTargets and Therapy Dove Medical Press, 2009 (2016), Seite 7169-7175 (DE-627)600307654 (DE-600)2495130-4 11786930 nnns year:2016 pages:7169-7175 https://doaj.org/article/8eb24fa1ff7945a998ded7ce01b1000e kostenfrei https://www.dovepress.com/effect-of-cyberknife-stereotactic-body-radiation-therapy-for-hepatocel-peer-reviewed-article-OTT kostenfrei https://doaj.org/toc/1178-6930 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2016 7169-7175
language	English
source	In OncoTargets and Therapy (2016), Seite 7169-7175 year:2016 pages:7169-7175
sourceStr	In OncoTargets and Therapy (2016), Seite 7169-7175 year:2016 pages:7169-7175
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	Hepatocellular carcinoma Hepatic toxicity CyberKnife stereotactic body radiation therapy (SBRT) Neoplasms. Tumors. Oncology. Including cancer and carcinogens
isfreeaccess_bool	true
container_title	OncoTargets and Therapy
authorswithroles_txt_mv	Liang P @@aut@@ Huang C @@aut@@ Liang S @@aut@@ Li Y @@aut@@ Huang S @@aut@@ Lian Z @@aut@@ Liu J @@aut@@ Tang Y @@aut@@ Lu H @@aut@@
publishDateDaySort_date	2016-01-01T00:00:00Z
hierarchy_top_id	600307654
id	DOAJ064852555
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ064852555</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230309042653.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230228s2016 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ064852555</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ8eb24fa1ff7945a998ded7ce01b1000e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC254-282</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Liang P</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Effect of CyberKnife stereotactic body radiation therapy for hepatocellular carcinoma on hepatic toxicity</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2016</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Ping Liang,1,* Cheng Huang,2,* Shi-Xiong Liang,2,3 Ye-Fei Li,3 Shang-Xiao Huang,2 Zu-Ping Lian,1 Jian-Min Liu,1 Yang Tang,1 Hai-Jie Lu4 1Department of Radiation Oncology, Ruikang Hospital Affiliated to Guangxi University of Chinese Medicine, 2Department of Radiation Oncology, Cancer Hospital, Guangxi Medical University, Nanning, 3Department of Radiation Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, 4Department of Radiation Oncology, Zhongshan Hospital of Xiamen University, Xiamen, Fujian, People&rsquo;s Republic of China *These authors contributed equally to this work Objective: To evaluate the safety of CyberKnife stereotactic body radiation therapy (SBRT) for hepatocellular carcinoma (HCC) patients and identify the treatment-related risk factors of hepatic toxicity.Materials and methods: One hundred and four HCC patients treated with CyberKnife SBRT were included in this study between August 2009 and December 2012. The average dose of prescribed radiation was 42.81+-4.78 Gy (28&ndash;55 Gy) with the average fraction size of 8&ndash;16 Gy to the planning target volume. The average fractions were 3.31+-0.81 (2&ndash;6 fractions). Response rates were determined, and the Child&ndash;Pugh (CP) score and class following CyberKnife SBRT were obtained to evaluate hepatic toxicity.Results: Seventeen patients experienced progression in CP class and 24 patients experienced CTCAE V. 4.0 grade 2&ndash;3 hepatic toxicity during the five-month follow-up period, while no patient experienced grade 4 liver toxicity. Multivariate analysis indicated that only V25 was an independent factor in grade 2&ndash;3 hepatic toxicity (P=0.029, &lt;0.05). Radiation-induced hepatic toxicity (RIHT), defined as an increase of at least two points within three months following CyberKnife SBRT, occurred in 13 of the 104 patients (13/104, 12.5%), and only the normal liver tissue was found to be associated with RIHT (P=0.008, &lt;0.05).Conclusion: CyberKnife SBRT is a feasible and safe treatment for HCC with regard to hepatic toxicity, while V25 and normal liver volume may be an independent factor of grade 2&ndash;3 hepatic toxicity and RIHT, respectively. Keywords: hepatocellular carcinoma, hepatic toxicity, CyberKnife stereotactic body radiation therapy (SBRT)</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Hepatocellular carcinoma</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Hepatic toxicity</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">CyberKnife stereotactic body radiation therapy (SBRT)</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Neoplasms. Tumors. Oncology. Including cancer and carcinogens</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Huang C</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Liang S</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Li Y</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Huang S</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Lian Z</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Liu J</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Tang Y</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Lu H</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">OncoTargets and Therapy</subfield><subfield code="d">Dove Medical Press, 2009</subfield><subfield code="g">(2016), Seite 7169-7175</subfield><subfield code="w">(DE-627)600307654</subfield><subfield code="w">(DE-600)2495130-4</subfield><subfield code="x">11786930</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">year:2016</subfield><subfield code="g">pages:7169-7175</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/8eb24fa1ff7945a998ded7ce01b1000e</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.dovepress.com/effect-of-cyberknife-stereotactic-body-radiation-therapy-for-hepatocel-peer-reviewed-article-OTT</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1178-6930</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="j">2016</subfield><subfield code="h">7169-7175</subfield></datafield></record></collection>
callnumber-first	R - Medicine
author	Liang P
spellingShingle	Liang P misc RC254-282 misc Hepatocellular carcinoma misc Hepatic toxicity misc CyberKnife stereotactic body radiation therapy (SBRT) misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens Effect of CyberKnife stereotactic body radiation therapy for hepatocellular carcinoma on hepatic toxicity
authorStr	Liang P
ppnlink_with_tag_str_mv	@@773@@(DE-627)600307654
format	electronic Article
delete_txt_mv	keep
author_role	aut aut aut aut aut aut aut aut aut
collection	DOAJ
remote_str	true
callnumber-label	RC254-282
illustrated	Not Illustrated
issn	11786930
topic_title	RC254-282 Effect of CyberKnife stereotactic body radiation therapy for hepatocellular carcinoma on hepatic toxicity Hepatocellular carcinoma Hepatic toxicity CyberKnife stereotactic body radiation therapy (SBRT)
topic	misc RC254-282 misc Hepatocellular carcinoma misc Hepatic toxicity misc CyberKnife stereotactic body radiation therapy (SBRT) misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens
topic_unstemmed	misc RC254-282 misc Hepatocellular carcinoma misc Hepatic toxicity misc CyberKnife stereotactic body radiation therapy (SBRT) misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens
topic_browse	misc RC254-282 misc Hepatocellular carcinoma misc Hepatic toxicity misc CyberKnife stereotactic body radiation therapy (SBRT) misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	OncoTargets and Therapy
hierarchy_parent_id	600307654
hierarchy_top_title	OncoTargets and Therapy
isfreeaccess_txt	true
familylinks_str_mv	(DE-627)600307654 (DE-600)2495130-4
title	Effect of CyberKnife stereotactic body radiation therapy for hepatocellular carcinoma on hepatic toxicity
ctrlnum	(DE-627)DOAJ064852555 (DE-599)DOAJ8eb24fa1ff7945a998ded7ce01b1000e
title_full	Effect of CyberKnife stereotactic body radiation therapy for hepatocellular carcinoma on hepatic toxicity
author_sort	Liang P
journal	OncoTargets and Therapy
journalStr	OncoTargets and Therapy
callnumber-first-code	R
lang_code	eng
isOA_bool	true
recordtype	marc
publishDateSort	2016
contenttype_str_mv	txt
container_start_page	7169
author_browse	Liang P Huang C Liang S Li Y Huang S Lian Z Liu J Tang Y Lu H
class	RC254-282
format_se	Elektronische Aufsätze
author-letter	Liang P
author2-role	verfasserin
title_sort	effect of cyberknife stereotactic body radiation therapy for hepatocellular carcinoma on hepatic toxicity
callnumber	RC254-282
title_auth	Effect of CyberKnife stereotactic body radiation therapy for hepatocellular carcinoma on hepatic toxicity
abstract	Ping Liang,1,* Cheng Huang,2,* Shi-Xiong Liang,2,3 Ye-Fei Li,3 Shang-Xiao Huang,2 Zu-Ping Lian,1 Jian-Min Liu,1 Yang Tang,1 Hai-Jie Lu4 1Department of Radiation Oncology, Ruikang Hospital Affiliated to Guangxi University of Chinese Medicine, 2Department of Radiation Oncology, Cancer Hospital, Guangxi Medical University, Nanning, 3Department of Radiation Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, 4Department of Radiation Oncology, Zhongshan Hospital of Xiamen University, Xiamen, Fujian, People’s Republic of China *These authors contributed equally to this work Objective: To evaluate the safety of CyberKnife stereotactic body radiation therapy (SBRT) for hepatocellular carcinoma (HCC) patients and identify the treatment-related risk factors of hepatic toxicity.Materials and methods: One hundred and four HCC patients treated with CyberKnife SBRT were included in this study between August 2009 and December 2012. The average dose of prescribed radiation was 42.81+-4.78 Gy (28–55 Gy) with the average fraction size of 8–16 Gy to the planning target volume. The average fractions were 3.31+-0.81 (2–6 fractions). Response rates were determined, and the Child–Pugh (CP) score and class following CyberKnife SBRT were obtained to evaluate hepatic toxicity.Results: Seventeen patients experienced progression in CP class and 24 patients experienced CTCAE V. 4.0 grade 2–3 hepatic toxicity during the five-month follow-up period, while no patient experienced grade 4 liver toxicity. Multivariate analysis indicated that only V25 was an independent factor in grade 2–3 hepatic toxicity (P=0.029, <0.05). Radiation-induced hepatic toxicity (RIHT), defined as an increase of at least two points within three months following CyberKnife SBRT, occurred in 13 of the 104 patients (13/104, 12.5%), and only the normal liver tissue was found to be associated with RIHT (P=0.008, <0.05).Conclusion: CyberKnife SBRT is a feasible and safe treatment for HCC with regard to hepatic toxicity, while V25 and normal liver volume may be an independent factor of grade 2–3 hepatic toxicity and RIHT, respectively. Keywords: hepatocellular carcinoma, hepatic toxicity, CyberKnife stereotactic body radiation therapy (SBRT)
abstractGer	Ping Liang,1,* Cheng Huang,2,* Shi-Xiong Liang,2,3 Ye-Fei Li,3 Shang-Xiao Huang,2 Zu-Ping Lian,1 Jian-Min Liu,1 Yang Tang,1 Hai-Jie Lu4 1Department of Radiation Oncology, Ruikang Hospital Affiliated to Guangxi University of Chinese Medicine, 2Department of Radiation Oncology, Cancer Hospital, Guangxi Medical University, Nanning, 3Department of Radiation Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, 4Department of Radiation Oncology, Zhongshan Hospital of Xiamen University, Xiamen, Fujian, People’s Republic of China *These authors contributed equally to this work Objective: To evaluate the safety of CyberKnife stereotactic body radiation therapy (SBRT) for hepatocellular carcinoma (HCC) patients and identify the treatment-related risk factors of hepatic toxicity.Materials and methods: One hundred and four HCC patients treated with CyberKnife SBRT were included in this study between August 2009 and December 2012. The average dose of prescribed radiation was 42.81+-4.78 Gy (28–55 Gy) with the average fraction size of 8–16 Gy to the planning target volume. The average fractions were 3.31+-0.81 (2–6 fractions). Response rates were determined, and the Child–Pugh (CP) score and class following CyberKnife SBRT were obtained to evaluate hepatic toxicity.Results: Seventeen patients experienced progression in CP class and 24 patients experienced CTCAE V. 4.0 grade 2–3 hepatic toxicity during the five-month follow-up period, while no patient experienced grade 4 liver toxicity. Multivariate analysis indicated that only V25 was an independent factor in grade 2–3 hepatic toxicity (P=0.029, <0.05). Radiation-induced hepatic toxicity (RIHT), defined as an increase of at least two points within three months following CyberKnife SBRT, occurred in 13 of the 104 patients (13/104, 12.5%), and only the normal liver tissue was found to be associated with RIHT (P=0.008, <0.05).Conclusion: CyberKnife SBRT is a feasible and safe treatment for HCC with regard to hepatic toxicity, while V25 and normal liver volume may be an independent factor of grade 2–3 hepatic toxicity and RIHT, respectively. Keywords: hepatocellular carcinoma, hepatic toxicity, CyberKnife stereotactic body radiation therapy (SBRT)
abstract_unstemmed	Ping Liang,1,* Cheng Huang,2,* Shi-Xiong Liang,2,3 Ye-Fei Li,3 Shang-Xiao Huang,2 Zu-Ping Lian,1 Jian-Min Liu,1 Yang Tang,1 Hai-Jie Lu4 1Department of Radiation Oncology, Ruikang Hospital Affiliated to Guangxi University of Chinese Medicine, 2Department of Radiation Oncology, Cancer Hospital, Guangxi Medical University, Nanning, 3Department of Radiation Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, 4Department of Radiation Oncology, Zhongshan Hospital of Xiamen University, Xiamen, Fujian, People’s Republic of China *These authors contributed equally to this work Objective: To evaluate the safety of CyberKnife stereotactic body radiation therapy (SBRT) for hepatocellular carcinoma (HCC) patients and identify the treatment-related risk factors of hepatic toxicity.Materials and methods: One hundred and four HCC patients treated with CyberKnife SBRT were included in this study between August 2009 and December 2012. The average dose of prescribed radiation was 42.81+-4.78 Gy (28–55 Gy) with the average fraction size of 8–16 Gy to the planning target volume. The average fractions were 3.31+-0.81 (2–6 fractions). Response rates were determined, and the Child–Pugh (CP) score and class following CyberKnife SBRT were obtained to evaluate hepatic toxicity.Results: Seventeen patients experienced progression in CP class and 24 patients experienced CTCAE V. 4.0 grade 2–3 hepatic toxicity during the five-month follow-up period, while no patient experienced grade 4 liver toxicity. Multivariate analysis indicated that only V25 was an independent factor in grade 2–3 hepatic toxicity (P=0.029, <0.05). Radiation-induced hepatic toxicity (RIHT), defined as an increase of at least two points within three months following CyberKnife SBRT, occurred in 13 of the 104 patients (13/104, 12.5%), and only the normal liver tissue was found to be associated with RIHT (P=0.008, <0.05).Conclusion: CyberKnife SBRT is a feasible and safe treatment for HCC with regard to hepatic toxicity, while V25 and normal liver volume may be an independent factor of grade 2–3 hepatic toxicity and RIHT, respectively. Keywords: hepatocellular carcinoma, hepatic toxicity, CyberKnife stereotactic body radiation therapy (SBRT)
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700
title_short	Effect of CyberKnife stereotactic body radiation therapy for hepatocellular carcinoma on hepatic toxicity
url	https://doaj.org/article/8eb24fa1ff7945a998ded7ce01b1000e https://www.dovepress.com/effect-of-cyberknife-stereotactic-body-radiation-therapy-for-hepatocel-peer-reviewed-article-OTT https://doaj.org/toc/1178-6930
remote_bool	true
author2	Huang C Liang S Li Y Huang S Lian Z Liu J Tang Y Lu H
author2Str	Huang C Liang S Li Y Huang S Lian Z Liu J Tang Y Lu H
ppnlink	600307654
callnumber-subject	RC - Internal Medicine
mediatype_str_mv	c
isOA_txt	true
hochschulschrift_bool	false
callnumber-a	RC254-282
up_date	2024-07-04T00:36:30.957Z
_version_	1803606704478224384
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ064852555</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230309042653.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230228s2016 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ064852555</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ8eb24fa1ff7945a998ded7ce01b1000e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC254-282</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Liang P</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Effect of CyberKnife stereotactic body radiation therapy for hepatocellular carcinoma on hepatic toxicity</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2016</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Ping Liang,1,* Cheng Huang,2,* Shi-Xiong Liang,2,3 Ye-Fei Li,3 Shang-Xiao Huang,2 Zu-Ping Lian,1 Jian-Min Liu,1 Yang Tang,1 Hai-Jie Lu4 1Department of Radiation Oncology, Ruikang Hospital Affiliated to Guangxi University of Chinese Medicine, 2Department of Radiation Oncology, Cancer Hospital, Guangxi Medical University, Nanning, 3Department of Radiation Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, 4Department of Radiation Oncology, Zhongshan Hospital of Xiamen University, Xiamen, Fujian, People&rsquo;s Republic of China *These authors contributed equally to this work Objective: To evaluate the safety of CyberKnife stereotactic body radiation therapy (SBRT) for hepatocellular carcinoma (HCC) patients and identify the treatment-related risk factors of hepatic toxicity.Materials and methods: One hundred and four HCC patients treated with CyberKnife SBRT were included in this study between August 2009 and December 2012. The average dose of prescribed radiation was 42.81+-4.78 Gy (28&ndash;55 Gy) with the average fraction size of 8&ndash;16 Gy to the planning target volume. The average fractions were 3.31+-0.81 (2&ndash;6 fractions). Response rates were determined, and the Child&ndash;Pugh (CP) score and class following CyberKnife SBRT were obtained to evaluate hepatic toxicity.Results: Seventeen patients experienced progression in CP class and 24 patients experienced CTCAE V. 4.0 grade 2&ndash;3 hepatic toxicity during the five-month follow-up period, while no patient experienced grade 4 liver toxicity. Multivariate analysis indicated that only V25 was an independent factor in grade 2&ndash;3 hepatic toxicity (P=0.029, &lt;0.05). Radiation-induced hepatic toxicity (RIHT), defined as an increase of at least two points within three months following CyberKnife SBRT, occurred in 13 of the 104 patients (13/104, 12.5%), and only the normal liver tissue was found to be associated with RIHT (P=0.008, &lt;0.05).Conclusion: CyberKnife SBRT is a feasible and safe treatment for HCC with regard to hepatic toxicity, while V25 and normal liver volume may be an independent factor of grade 2&ndash;3 hepatic toxicity and RIHT, respectively. Keywords: hepatocellular carcinoma, hepatic toxicity, CyberKnife stereotactic body radiation therapy (SBRT)</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Hepatocellular carcinoma</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Hepatic toxicity</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">CyberKnife stereotactic body radiation therapy (SBRT)</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Neoplasms. Tumors. Oncology. Including cancer and carcinogens</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Huang C</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Liang S</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Li Y</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Huang S</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Lian Z</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Liu J</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Tang Y</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Lu H</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">OncoTargets and Therapy</subfield><subfield code="d">Dove Medical Press, 2009</subfield><subfield code="g">(2016), Seite 7169-7175</subfield><subfield code="w">(DE-627)600307654</subfield><subfield code="w">(DE-600)2495130-4</subfield><subfield code="x">11786930</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">year:2016</subfield><subfield code="g">pages:7169-7175</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/8eb24fa1ff7945a998ded7ce01b1000e</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.dovepress.com/effect-of-cyberknife-stereotactic-body-radiation-therapy-for-hepatocel-peer-reviewed-article-OTT</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1178-6930</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="j">2016</subfield><subfield code="h">7169-7175</subfield></datafield></record></collection>
score	7.4007425

Nicht das Richtige dabei?

Schreiben Sie uns!

Effect of CyberKnife stereotactic body radiation therapy for hepatocellular carcinoma on hepatic toxicity

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?